Amphastar Pharmaceuticals (AMPH) Q4 2025 earnings summary

Executive summary

• 2025 was pivotal, marked by strong commercial execution, scientific innovation, and double-digit BAQSIMI® growth, with FDA approvals for iron sucrose, teriparatide, and Ipratropium Bromide HFA Inhalation Aerosol.

• The company advanced its proprietary pipeline, adding novel peptides in oncology, ophthalmology, and a synthetic corticotropin program in immunology.

• Operates a fully integrated business model with in-house R&D, manufacturing, and marketing, emphasizing efficiency and high net income margins.

• Proprietary and biosimilar products are projected to comprise 85% of the pipeline by 2026, up from 37% in 2021.

• Operational discipline was maintained, with tightened expenses and prioritization of long-term investments despite modest revenue decline due to legacy product headwinds.

Financial highlights

• Full-year 2025 net revenues were $719.9 million, with BAQSIMI® contributing $185.4 million (up 46% YoY) and Primatene MIST® $108.7 million (up 7% YoY).

• Q4 2025 revenues were $183.1 million (down 2% YoY); Q4 gross profit was $85.7 million (46.8% margin), and full-year gross profit was $356.1 million (49.5% margin).

• Adjusted non-GAAP net income for 2025 was $156.6 million ($3.25/share); Q4 adjusted EPS was $0.73.

• Operating cash flow for the year was $156.1 million.

• Adjusted net income margin reached 27.4% in 2024, projected at 21.8% in 2025.

Outlook and guidance

• 2026 revenue is expected to grow mid-to-high single digits, driven by Ipratropium Bromide launch and continued BAQSIMI® and Primatene MIST® growth.

• BAQSIMI® peak annual sales projected at $250M–$275M, with mid single-digit growth in 2026; Primatene MIST® forecasted for high single-digit growth.

• Gross margins expected to decline due to pricing pressure on high-margin legacy products and higher input costs.

• Increased R&D and capital spending planned, especially for pipeline and facility expansion.

• Focus for 2026 is on advancing pipeline programs, securing approvals, and scaling U.S. manufacturing.